Decisions relating to the funded brands of some anti-retroviral treatments for HIV


20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in the treatment of HIV infection.

These decisions were the subject of a consultation letter dated 16 October 2018. There were no changes to the original proposal.

These decisions relate only to which brand of the treatment will be funded. There are no changes to funding criteria or the range of treatments funded.

Read PHARMAC notification

Michael Wonder

Posted by:

Michael Wonder